<!DOCTYPE HTML>
<!--
	Massively by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>My Portfolio</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
		<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper" class="fade-in">

				<!-- Intro -->
					<div id="intro">
						<h1>My Portfolio</h1>
						<h3>Research Methods and Professional Practice</h3>
						<ul class="actions">
							<li><a href="#header" class="button icon solid solo fa-arrow-down scrolly">Continue</a></li>
						</ul>
					</div>

				<!-- Nav -->
					<nav id="nav">
						<ul class="icons">
							<li><a href="https://github.com/pmatkowska94/e-portfolio.pmatkowska" class="icon brands fa-github"><span class="label">GitHub</span></a></li>
						</ul>
					</nav>

				<!-- Main -->
					<div id="main">

						<!-- Featured Post -->
							<article class="post featured">
								<header class="major">
									<h2>Peer Review</h2>
									<p>Comparative Evaluation of Machine Learning Approaches for Drug–Drug Interaction Prediction</p>
								</header>
								<img src="images/RM_peer_rev.jpg" alt="" style="width: 100%; height: auto; max-width: 100%;" /> 
    <h2>Peer Review: Comparative Evaluation of Machine Learning Approaches for Drug–Drug Interaction Prediction</h2>

<p>This analysis presents a comparative evaluation of two research papers in the field of computational pharmacology, both of which apply machine learning techniques to address challenges related to drug–drug interactions (DDIs), yet through different research methodologies. The first paper utilises regression-based models, while the second adopts deep learning classification. Their respective methodological designs, data strategies, and implications are considered below.</p>

<p>
Gill at all., 2023 investigate whether regression-based machine learning models can predict pharmacokinetic DDIs by quantifying changes in drug exposure, instead of merely classifying interactions. This objective is particularly relevant to current pharmaceutical research, as it offers a method for assessing DDIs early in the drug development pipeline, where experimental studies are expensive and time-consuming. From both scientific and clinical perspectives, this contribution is meaningful and aligns well with ongoing shifts towards predictive modelling in pharmacology. The data employed are drawn from two well-established sources—SimCYP and the Washington DDI database ensuring data credibility. The feature set includes clinical, chemical, and in silico data, and the methodology incorporates preprocessing techniques such as standardisation and one-hot encoding. Notably, the authors use supervised regression models (support vector regression, random forest, elastic net), evaluated via nested cross-validation. They explicitly exclude deep learning due to the limited sample size and interpretability challenges. Additionally, SHAP is used to interpret feature importance, enhancing model transparency.
</p>
<p>
  The data employed are drawn from two well-established sources—SimCYP and the Washington DDI database—ensuring data credibility. The feature set includes clinical, chemical, and in silico data,
  and the methodology incorporates preprocessing techniques such as standardisation and one-hot encoding. Notably, the authors use supervised regression models (support vector regression, random 
  forest, elastic net), evaluated via nested cross-validation. Deep learning was explicitly excluded due to the limited sample size and interpretability challenges. SHAP was used to interpret
  feature importance, enhancing model transparency.
</p>
<p>
  The research’s conclusions are supported by diverse metrics (R², RMSE, twofold error), and it offers a candid discussion of the limitations, particularly the imbalance in the distribution of the target variable. This issue was statistically confirmed using the Kolmogorov–Smirnov test, revealing the model’s tendency to underperform in specific scenarios, such as predicting strong inhibition cases. Although SVR performed slightly better, all models significantly outperformed the baseline, reinforcing the argument that early-phase data can be predictive. The authors also suggest future directions, including addressing data imbalance. To enhance this work, more proactive testing of techniques such as SMOTE could be incorporated to address the underrepresentation of certain classes. Overall, this paper demonstrates robust methodology, sound data practices, and thoughtful reflection on limitations, making it a strong example of applied regression ML in drug discovery.
</p>
<p>
  Ryu, Kim & Lee, 2018 take a different approach, using a deep learning architecture to classify 86 types of DDIs using only drug names and chemical structures. The paper addresses a clear research gap, namely the lack of interaction-type predictions and the high data requirements of many existing models. It aims to offer a lightweight, accessible model that avoids manual feature engineering. The use of the DrugBank dataset as a gold standard and the extension of the model to include drug–food interactions shows an intention to make the model more comprehensive and clinically applicable. The authors benchmark their DeepDDI model against other classifiers (random forest, KNN), reinforcing the credibility of their results. The model’s ability to output natural language interpretations of interactions enhances accessibility, especially for clinical users. Importantly, the paper acknowledges the limitations of modelling only pairwise interactions and omitting factors like drug dosage or patient-specific variables.
<p>
  Despite high performance, further analysis of misclassified cases would have strengthened transparency. Suggestions for future enhancement include extending the model to handle multi-drug interactions and incorporating pharmacokinetic variables such as dose and concentration. Additional improvements could involve refining interpretability with visual outputs and confidence scoring, as well as addressing class imbalance during training. The authors also note the potential of using more advanced architectures, such as graph neural networks, and integrating patient-specific features for personalised predictions. Overall, this paper makes a notable contribution to the growing body of work on AI applications in drug safety, particularly by lowering the entry barrier to interaction prediction and offering a scalable and practical solution.
</p>
<p>
In conclusion, Gill et al., 2023 employ a rigorous regression methodology supported by traditional evaluation metrics and feature interpretability techniques, while Ryu, Kim & Lee, 2018 demonstrate the utility of deep learning in predicting complex interaction types with minimal input features. Both papers contribute significantly to the field by addressing different but complementary aspects of DDI prediction. Their methodological appropriateness, solid data handling, and clear support for conclusions reinforce their scientific value. Suggested enhancements for both works, ranging from handling data imbalance to expanding model complexity and input diversity, reflect logical next steps in this evolving research domain.
</p>


<h3>References</h3>
<ul>
  <li>
    Gill J, Moullet M, Martinsson A, Miljković F, Williamson B, Arends RH, Pilla Reddy V. (2023) Evaluating the performance of machine-learning regression models for pharmacokinetic
    drug-drug interactions. <em>CPT Pharmacometrics Syst Pharmacol</em>. 122-134. doi: 10.1002/psp4.12884.
  </li>
  <li>
    Ryu JY, Kim HU, Lee SY. (2018) Deep learning improves prediction of drug-drug and drug-food interactions. <em>Proc Natl Acad Sci U S A</em>. 115(18):E4304-E4311. doi: 10.1073/pnas.1803294115
  </li>
</ul>

             
                <ul class="actions special">
										<li><a href="index.html" class="button">Home</a></li>
									</ul>
                
							</article>

					</div>

				<!-- Footer -->
					<footer id="footer">
					</footer>

				<!-- Copyright -->
					<div id="copyright">
						<ul><li>&copy; </li><li>Design: <a href="https://html5up.net">HTML5 UP</a></li></ul>
					</div>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/jquery.scrollex.min.js"></script>
			<script src="assets/js/jquery.scrolly.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

	</body>
</html>
